Article Text

Download PDFPDF
The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong
  1. Ka-On Lam1,
  2. Kin-Chung Lee2,
  3. Joanne Chiu3,
  4. Victor Ho-Fun Lee1,
  5. Roland Leung3,
  6. T S Choy1,
  7. Thomas Yau3
  1. 1Department of Clinical Oncology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
  2. 2Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong
  3. 3Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
  1. Correspondence to Dr Thomas Yau, Department of Medicine, The University of Hong Kong, Room 405, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, Hong Kong; the{at}


Purpose of the study To evaluate the benefits and tolerability of regorafenib in the real-world setting, we performed a multicentre analysis in Hong Kong.

Study design Individual patient data were retrieved from three leading oncology centres in Hong Kong for analyses. All patients with metastatic colorectal cancer (mCRC) treated with regorafenib after failure of all standard systemic options were included.

Results From July 2013 to December 2015, 45 consecutive patients treated with regorafenib for mCRC were analysed. The median age was 63. Twenty patients were started at 160 mg, while the other 25 patients were started at a lower dose. The median progression-free survival was 15.6 weeks (95% CI 13.1 to 18.1 weeks) and the median overall survival was 30.4 weeks (95% CI 16.6 to 44.3 weeks). Among the 31 evaluable patients, only 1 patient (3.2%) achieved partial response and another 10 patients (32.3%) had stable disease. The commonest grade 3 non-haematological adverse event (AE) was hand–foot skin reaction (26.7%) and the commonest grade 3 or 4 haematological AE was anaemia (8.9%). Notably, patients who were started on a lower dose of regorafenib had significantly lower risk of grade 3 treatment-emergent AEs. Overall, 78.3% of the patients had dose reduction during the first and second cycles. Patients older than 65 years were more likely to experience cycle suspension and require dose reduction.

Conclusions Our study confirmed the efficacy and tolerability of regorafenib in the real-world setting. It also suggested that individualised dosing of regorafenib in patients with mCRC might result in better clinical outcomes.

  • refractory
  • regorafenib
  • individualized medicine
  • metastatic colorectal cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors K-OL, K-CL, JC, VH-FL, RL, TSC and TY conceived of the study, and participated in its design and coordination and helped draft the manuscript. K-OL, K-CL and TY provided study materials and patients. K-OL performed the statistical analysis. All authors read and approved the final manuscript.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.